2）Ohta N, Hori M, Takahashi A, Ogura M, Makino H, Tamanaha T, et al. Proprotein convertase subtilisin/kexin 9 (PCSK9) V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. J Clin Lipidol 2016; 10: 547-55.3）Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano 5）Harada-Shiba M, Takagi A, Marutsuka K, Moriguchi S, Yagyu H, Ishibashi S, et al. Disruption of autosomal recessive hypercholesterolemia gene shows different phenotype in vitro and in vivo. Circ Res 2004; 95: 945-52.1）Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri M, Inoue T, et al. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type9(PCSK9) gain-of-function mutation. Atherosclerosis 2014; 236: 54-61.H, et al. Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb 2021; 28: 665-78.4）Takayama K, Akita N, Mimura N, Akahira R, Taniguchi Y, Ikeda M, et al. Generation of safe and therapeutically effective human induced pluripotent stem cell-derived hepatocyte-like cells for regenerative medicine. Hepatol Commun 2017; 12: 1058-69.6）Tada H, Kawashiri M, Ikewaki K, Terao Y, Noguchi T, Nakanishi C, et al. Altered metabolism of low-density ipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet 2012; 5: 35-41.7）Doi T, Hori M, Harada-Shiba M, Kataoka Y, Onozuka D, Nishimura K, et al. Patients with LDLR and PCSK9 gene variants experienced higher incidence of cardiovascular outcomes in heterozygous familial hypercholesterolemia. J Am Heart Assoc 2021: 10: e018263.8）Kajiwara M, Aoi T, Okita K, Takahashi R, Inoue H, Takayama N, et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012; 109: 12538-43.53文 献
元のページ ../index.html#67